Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(21):1576; doi:10.1093/jnci/95.21.1576
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Wang, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wang, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 Oxford University Press

NEWS

In Brief

Linda Wang

The first 10% of the full text of this article appears below.

Letrozole Decreases Risk of Breast Cancer Recurrence, Study Finds

A new study found that women who took the aromatase inhibitor letrozole after completing 5 years of tamoxifen therapy had a 43% reduction in risk of breast cancer recurrence compared with women who took a placebo. The 5-year study was stopped early because of the positive results so that women in the placebo arm of the trial would have the opportunity to take the active drug.

. . . [Full Text of this Article]

Mononucleosis Associated with Risk of Hodgkin’s Lymphoma

Equal Treatment Reduces Racial Disparities in Childhood Leukemia Outcomes


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?